Mr Paras Singh

Consultant Urologist

MBBS MRCS MD FRCS (UROLOGY)

Mr Paras Singh qualified from Institute of Medical Sciences, Varanasi, India. He moved to the United Kingdom for his higher surgical training in Urology. He was awarded an MD at Lancaster University for his work on racial differences in the metabolising enzymes in the human prostate.

Mr Singh received his urology training in London working at University College Hospital, Royal Free Hospital and Whipps Cross Hospital. He was appointed as a consultant urological surgeon in 2014.

He has a broad general urology practice with special interests in benign prostatic disease (medical management and minimally invasive therapy – TURP / TURiS), stone disease, prostate cancer diagnostics and urothelial cancers (endoscopic management of bladder cancer and upper tract cancer). He introduced MRI fusion prostate biopsies at the Royal Free London NHS Foundation Trust. He is a core member of the bladder cancer and prostate cancer multi-disciplinary teams at the Royal Free London NHS Foundation Trust.

Mr Singh is the principal investigator in several prostate and bladder cancer trials.

Originally from Nepal, he is married with two children. His daughter was the youngest Olympian at Rio 2016 at the age of 13. He is actively involved with several Nepalese organisations in the UK and with charity work in Nepal.

Specialities

  • Urology

Special interests

  • Benign prostatic disease
  • Prostate cancer
  • Urothelial cancers
  • Stone diseases.

Research interests

  • Ultrasound imaging and classification of thyroid nodules.

Procedures Offered

  • Urology

Recent presentations

Transforming the prostate cancer pathway by incorporating same-day multiparametric prostate MRI (mpMRI) scans and prostate biopsies – prompt diagnosis with improved cancer waiting times

Cohen D, Roy A, Kaul A, McCarthy F, Smith G, Singh P

Poster presentation at Leaders in Healthcare Conference, Liverpool (30th Oct – 1st November 2017)

MRI/TRUS fusion prostate biopsy: can we omit concurrent systematic biopsies? Dinneen E, Gresty H, Goode A, Train M, Grant L, Marcus A, Smith G, Singh P

Poster presentation at British Association of Annual Meeting, Glasgow (27/6/2017)

One-stop prostate clinic incorporating same-day multi-parametric prostate MRI and prostate biopsies: initial experience and impact on pathway compliance.

Cohen D, Roy A, McCarthy F, Goode A, Train M, Marcus A, Grant L, Smith G, Singh P

Poster presentation at British Association of Annual Meeting, Glasgow (27/6/2017)

Advances in endoscopic management of upper tract transitional cell cancer (TCC).

Annual National Meeting, SIU UK 2016, London (20/5/2016)

Variation in gentamicin prophylaxis for urological procedures: evidence based or traditional practice?

AK Kaul, SY Sim, V Mishra, I Balakrishnan, P Singh

Poster presentation at British Association of Annual Meeting, Manchester (16/6/2015)

Antibiotic Prophylaxis for Urological Procedures across the UK: why such variations in practice?

AK Kaul, S Sing, V Mishra, I Balakrishnan, P Singh

Poster presentation at British Association of Annual Meeting, Glasgow (16/6/2015)

The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. Valerio M, Anele C, Bott SR, Charman SC, van der Meulen J, El-Mahallawi H, Emara AM, Freeman A, Jameson C, Hindley RG, Montgomery BS, Singh PB, Ahmed HU, Emberton M. J Urol. 2016 May;195(5):1403-8. PMID: 26741696

Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer. Valerio M, Anele C, Charman SC, van der Meulen J, Freeman A, Jameson C, Singh PB, Emberton M, Ahmed HU. BJU Int. 2016 Sep;118(3):384-90. PMID: 26332050

Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, Arya M, Jameson C, Freeman A, Emberton M, Ahmed HU. Eur Urol. 2014 Jul;66(1):12-9. PMID: 24207133

Segregation of human prostate tissues classified high-risk (UK) versus low-risk (India) for adenocarcinoma using Fourier-transform infrared or Raman microspectroscopy coupled with discriminant analysis. Patel II, Trevisan J, Singh PB, Nicholson CM, Krishnan RK, Matanhelia SS, Martin FL. Anal Bioanal Chem. 2011 Aug;401(3):969-82. PMID: 21139866

Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites. Martin FL, Patel II, Sozeri O, Singh PB, Ragavan N, Nicholson CM, Frei E, Meinl W, Glatt H, Phillips DH, Arlt VM. Prostate. 2010 Oct 1;70(14):1586-99. PMID: 20687231

SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, Berney DM, Møller H, Reuter VE, Scardino P, Cuzick J, Ragavan N, Singh PB, Martin FL, Butler CM, Cooper CS, Swain A; Transatlantic Prostate Group. Cancer Res. 2010 Feb 1;70(3):979-87. PMID: 20103652

Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Singh PB, Ragavan N, Ashton KM, Basu P, Nadeem SM, Nicholson CM, Krishna RK, Matanhelia SS, Martin FL. Asian J Androl. 2010 Mar;12(2):203-14. PMID: 19935673

Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience. Singh PB, Nicholson CM, Ragavan N, Blades RA, Martin FL, Matanhelia SS. BMC Urol. 2009 May 27;9:3. PMID: 19473479

Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate. John K, Ragavan N, Pratt MM, Singh PB, Al-Buheissi S, Matanhelia SS, Phillips DH, Poirier MC, Martin FL. Prostate. 2009 Apr 1;69(5):505-19. PMID: 19143007

Use of tissue ink to maintain identification of individual cores on needle biopsies of the prostate. Singh PB, Saw NK, Haq A, Blades RA, Martin FL, Matanhelia SS, Nicholson CM. J Clin Pathol. 2008 Sep;61(9):1055-7. PMID: 18641411

A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Singh PB, Matanhelia SS, Martin FL. Eur J Cancer. 2008 May;44(7):928-36.

An integrated laparoscopic simulator (i-Sim) to develop surgical skills outside the operating theatre: a novel means to improve training facilities in the UK. Singh PB, Saw NK, Mokete M, Martin FL, Matanhelia SS. Int J Surg. 2008 Feb;6(1):64-70. PMID: 17804310

Letters

Time to Rethink PSA Screening. Singh PB, Ahmed HU, Simmons L, Freeman A, Emberton M. Arch Intern Med. 2011 Mar 28;171(6):595. PMID: 21444857

Active Surveillance: Is There a Need for Better Risk Stratification at the Outset? Singh PB, Ahmed HU, Emberton M. J Clin Oncol. 2010. PMID: 20697073

The risk of prostate cancer amongst South Asian men in southern England: the PROCESS cohort study. Singh PB, Ragavan N, Martin FL. BJU Int. 2009 Feb;103(4):553. PMID: 19187348

Book chapter

Prostate Biopsy. In Prostate Cancer: A Comprehensive Perspective (2013)